INFIQ (Infinity Pharmaceuticals) Days Payable: 445.49 (As of Jun. 2023)


INFIQ Infinity Pharmaceuticals Inc INFIQ
16 GF Score
Price $0.00
View Full Analysis

What is Infinity Pharmaceuticals Days Payable?

Infinity Pharmaceuticals INFIQ -99.00% 16 Days Payable is 445.49 as of Jun. 2023. GuruFocus rates INFIQ with a GF Score™ of 16/100.

Infinity Pharmaceuticals's average Accounts Payable for the three months ended in Jun. 2023 was $1.72 Mil. Infinity Pharmaceuticals's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.35 Mil. Hence, Infinity Pharmaceuticals's Days Payable for the three months ended in Jun. 2023 was 445.49.

The historical rank and industry rank for Infinity Pharmaceuticals's Days Payable or its related term are showing as below:

INFIQ's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84
* Ranked among companies with meaningful Days Payable only.

Infinity Pharmaceuticals's Days Payable increased from Jun. 2022 (420.65) to Jun. 2023 (445.49). It may suggest that Infinity Pharmaceuticals delayed paying its suppliers.

Infinity Pharmaceuticals Days Payable Historical Data

* Premium members only.

The historical data trend for Infinity Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infinity Pharmaceuticals Days Payable Chart

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,380.00 70.37 810.07 863.94 785.23

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 420.65 400.42 886.97 655.92 445.49

INFIQ vs CLCS, RVLPQ, IVRN: Days Payable Comparison

For the Biotechnology subindustry, Infinity Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infinity Pharmaceuticals Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Days Payable falls into.


INFIQ
16GF Score
Infinity Pharmaceuticals Inc INFIQ
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infinity Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Infinity Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

Days Payable (A: Dec. 2022 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2021 ) + Accounts Payable (A: Dec. 2022 )) / count ) / Cost of Goods Sold (A: Dec. 2022 )*Days in Period
=( (2.32 + 4.405) / 2 ) / 1.563*365
=3.3625 / 1.563*365
=785.23

Infinity Pharmaceuticals's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

Days Payable (Q: Jun. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Mar. 2023 ) + Accounts Payable (Q: Jun. 2023 )) / count ) / Cost of Goods Sold (Q: Jun. 2023 )*Days in Period
=( (1.935 + 1.502) / 2 ) / 0.352*365 / 4
=1.7185 / 0.352*365 / 4
=445.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 445.49 mean?
Infinity Pharmaceuticals (INFIQ) has a Days Payable of 445.49 as of Jun. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Infinity Pharmaceuticals and its competitors.
Is Infinity Pharmaceuticals' Days Payable too high?
Infinity Pharmaceuticals' current Days Payable is 445.49. The Biotechnology industry median Days Payable is 112.84. Infinity Pharmaceuticals' value of 445.49 is 294.8% above this industry median. Overall, Infinity Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Infinity Pharmaceuticals' Days Payable compare to CLCS and RVLPQ?
Infinity Pharmaceuticals' Days Payable of 445.49 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 112.84. Infinity Pharmaceuticals' value of 445.49 is 294.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infinity Pharmaceuticals's current Days Payable of 445.49 is 294.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Infinity Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infinity Pharmaceuticals's current Days Payable is 445.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinity Pharmaceuticals stock overvalued right now?
Infinity Pharmaceuticals (INFIQ) has a current Days Payable of 445.49. The current Days Payable is 445.49 and 294.8% above the Biotechnology industry median of 112.84. Infinity Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Infinity Pharmaceuticals (INFIQ), the current Days Payable is 445.49 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infinity Pharmaceuticals Business Description

Address 1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for people with cancer. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. It is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
16GF Score

Get the complete analysis for INFIQ

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price